Lysodren (Mitotane) Patent Expiration, LOE Window & CMS Spending

Lysodren (Mitotane) by Esteve Sa: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $3.8M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEsteve Sa
FDA Application & PathwayN016885 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.8M
2024 Medicare Part D Spend$2.7M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 203.6% 2-yr change)